Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × adagrasib × Clear all

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Phase 2 Recruiting

535 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06026410 2026-04-14

FIT-001

Phase 1 Recruiting

300 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Colorectal Neoplasms

NCT06248606 2026-04-08

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Phase 2 Recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06875310 2026-04-07

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Phase 3 Recruiting

630 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05853575 2026-03-27

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Phase 2 Active not recruiting

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT04613596 2026-03-18

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Phase 2/3 Recruiting

806 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07382726 2026-02-20

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

Phase 1 Not yet recruiting

18 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05578092 2026-02-19

A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Phase 1 Terminated

64 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Colorectal Neoplasms

NCT05673187 2026-01-21

ADEPPT

Phase 2 Active not recruiting

68 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06764771 2025-12-17

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Phase 1 Active not recruiting

437 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

NCT06039384 2025-08-03

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Phase 1 Terminated

6 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06024174 2025-07-22

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Phase 1/2 Terminated

5 enrolled 9 charts

GastrointestinalThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05375994 2025-05-18

RAMP204

Phase 1/2 Active not recruiting

85 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04330664 2025-04-04

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Phase 1 Completed

86 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04685135 2025-01-22

KRYSTAL-12

Phase 3 Active not recruiting

453 enrolled 20 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04975256 2024-12-16

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Phase 1 Terminated

7 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Clinical Trials

Krascendo 1

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

FIT-001

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

ADEPPT

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

RAMP204

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

KRYSTAL-12

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)